SCHEMBL16249334

SCHEMBL16249334

CON(C)C(=O)[C@@H]1CC[C@H](N(Cc2ccc(-c3ccccc3)cc2)C(=O)OC(C)(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.44
NR1H4 Q96RI1 1/20 0.42
KDM1A O60341 3/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
FASN P49327 3/20 0.37
USP30 Q70CQ3 1/20 0.37
BCL9 O00512 1/20 0.36
CTNNB1 P35222 1/20 0.36
PTPRB P23467 1/20 0.36
PTPN11 Q06124 1/20 0.36
CETP P11597 1/20 0.36
CYP2D6 P10635 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
HDAC3 O15379 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897710 0.91 HSD11B1 (0.46) HSD11B1NR1H4KDM1AHDAC8HDAC6
SCHEMBL14897752 0.88 HSD11B1 (0.48) HSD11B1NR1H4KDM1AHDAC8HDAC6
SCHEMBL18323855 0.87 HSD11B1 (0.43) HSD11B1NR1H4GPR119JAK2JAK1
SCHEMBL895983 0.87 HSD11B1 (0.51) HSD11B1NR1H4KDM1AHDAC8HDAC6
SCHEMBL14896930 0.80 HSD11B1 (0.44) HSD11B1NR1H4KDM1AHDAC8HDAC6
SCHEMBL16249333 0.80 HSD11B1 (0.49) HSD11B1NR1H4GPR119USP30HDAC3
SCHEMBL16241247 0.78 HSD11B1 (0.45) HSD11B1NR1H4KDM1AHDAC8HDAC6
SCHEMBL1536195 0.77 MEN1 (0.47) JAK2JAK1
SCHEMBL1536196 0.77 MEN1 (0.47) JAK2JAK1
SCHEMBL4348952 0.77 MEN1 (0.47) JAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-11-20 US disclosed
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS MARS, INCORPORATED 2014-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343019-A1 INHIBITORS OF ARGINASE AND THEIR THERAPEUTIC APPLICATIONS ARG1, ARG2, PRMT1 HSD11B1 1790/4885NR1H4 519/4885KDM1A 360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.